title: Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
abstract: The combination of cytotoxic therapies and antiangiogenic agents is emerging as a most promising strategy in the treatment of malignant tumors. However, the timing and sequencing of these treatments seem to play essential roles in achieving a synergic outcome. Using a mathematical modeling approach that is grounded on available experimental data, we investigate the spatial and temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Our model suggests that the experimental success of the nanoscale delivery system depends crucially on the trapping of chemotherapeutic agents within the tumor tissue. The numerical results also indicate that substantial further improvements in the efficiency of the nanoscale delivery system can be achieved through an adjustment of the temporal targeting mechanism.
authors: Department of Applied Mathematics, University of Waterloo, Waterloo, ON, Canada. kohandel@math.uwaterloo.ca
authors: M
authors: M
authors: Kohandel
authors: C A
authors: CA
authors: Haselwandter
authors: M
authors: M
authors: Kardar
authors: S
authors: S
authors: Sengupta
authors: S
authors: S
authors: Sivaloganathan
mesh_terms: D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001632:Bibenzyls / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001682:Biological Availability; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000473:pathology; D003198:Computer Simulation; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D004357:Drug Synergism; D008081:Liposomes; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008954:Models, Biological; D053758:Nanoparticles; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001632:Bibenzyls; D008081:Liposomes; C040105:combretastatin; D004317:Doxorubicin